Table 1.
Patient, tumor and treatment characteristics
| n | % | N | |
|---|---|---|---|
| médiane | [min-max] | ||
| Center | 91 | ||
| CFB | 16 | 17.6% | |
| CLB | 40 | 44% | |
| ICL | 28 | 30.8% | |
| IGR | 7 | 7.7% | |
| Age | 63.43 | [42.39–87.34] | 91 |
| Gender | 91 | ||
| F | 33 | 36.3% | |
| M | 58 | 63.7% | |
| PS | 90 | ||
| 0 | 39 | 43.3% | |
| 1 | 43 | 47.8% | |
| 2 | 8 | 8.9% | |
| Smoker (current or former) | 73 | 85.9% | 85 |
| Respiratory comorbidity | 26 | 29.2% | 89 |
| Cardiovascular comorbidity | 24 | 27.3% | 88 |
| Other cancer history | 19 | 21.6% | 88 |
| Other significant comorbidity | 21 | 23.9% | 88 |
| Histology | 91 | ||
| Adenocarcinoma | 59 | 64.8% | |
| Squamous cell | 16 | 17.6% | |
| Small Cell Lung Cancer | 8 | 8.8% | |
| Other | 8 | 8.8% | |
| Molecular alteration | 18 | 19.8% | 91 |
| EGFR | 8 | 9% | |
| ALK | 2 | 2.2% | |
| KRAS | 4 | 4.5% | |
| HER2 | 2 | 2.3% | |
| cMET amplification | 1 | 1.1% | |
| cMET mutation | 1 | 1.1% | |
| T | 89 | ||
| T1 | 18 | 20.2% | |
| T2 | 35 | 39.3% | |
| T3 | 25 | 28.1% | |
| T4 | 11 | 12.4% | |
| N | 89 | ||
| N0 | 31 | 34.8% | |
| N1 | 16 | 18% | |
| N2 | 26 | 29.2% | |
| N3 | 14 | 15.7% | |
| Nx | 2 | 2.2% | |
| Pre-therapeutic PET-TDM | 79 | 87.8% | 90 |
| Metastase(s) operability | 91 | ||
| Yes | 7 | 7.7% | |
| No | 41 | 45.1% | |
| Not reported | 43 | 47.3% | |
| Controlled primitive lesion | 77 | 84.6% | 91 |
| Number of metastase(s) | 91 | ||
| 1 | 83 | 91.2% | |
| > = 2 | 8 | 8.8% | |
| Characteristics of metastatic evolution | 91 | ||
| Metachronous | 63 | 69.2% | |
| Synchronous | 28 | 30.8% | |
| Indication | 91 | ||
| Oligopersistance | 18 | 19.8% | |
| Oligometastatic | 10 | 11% | |
| Oligoprogression | 18 | 19.8% | |
| Oligorecurrence | 45 | 49.5% | |
| Treated site | 99 | ||
| Liver | 12 | 12.1% | |
| Lymph node | 7 | 7.1% | |
| Bone | 20 | 20.2% | |
| Lung | 21 | 21.2% | |
| Spine | 12 | 12.1% | |
| Adrenal | 27 | 27.3% | |
| Contralateral to primitive lesion | 13 | 48.1% | 27 |
| Homolateral to primitive lesion | 14 | 51.9% | 27 |
| Ongoing systemic treatment before irradiation | 91 | ||
| No | 58 | 63.7% | |
| Yes | 33 | 36.3% | |
| Systemic treatment interruption during irradiation | 33 | ||
| No | 1 | 2.9% | |
| Yes | 32 | 97.1% | |
CFB Centre François Baclesse, CLB Centre Léon Bérard, ICL Institut de Cancérologie de Lorraine, IGR Institut Gustave Roussy